Home > Insider Trading > Filing (0001358403-16-000130)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1358403	Bellicum Pharmaceuticals Inc	BLCM	Pharmaceutical Preparations (2834)	201450200

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1626892	Annemarie Moseley	C/O Bellicum Pharmaceuticals, Inc. 2130 W. Holcombe Blvd., Ste. 800 Houston TX 77030	Coo/Evp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-01-04	35,000	$2.55	35,251	No	4	M	Direct
Common Stock	Disposition	2016-01-04	32,700	$19.01	2,551	No	4	S	Direct
Common Stock	Disposition	2016-01-04	2,300	$19.96	251	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (right to buy)	Acquisiton	2016-01-04	125,000	$0.00	125,000	$19.00
Common Stock	Stock Option (right to buy)	Disposition	2016-01-04	35,000	$0.00	35,000	$2.55

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
125,000		2026-01-03	No	4	A	Direct
18,235		2021-11-08	No	4	M	Direct

Footnotes

Includes 129 shares acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2015.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2015.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.71 to $19.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.71 to $20.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
25% of the shares subject to the stock option vest and become exercisable on January 4, 2017, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
25% of the shares subject to the stock option vest and became exercisable on November 9, 2012, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.